Buy DDAVP

DDAVP

What is DDAVP?

DDAVP is a brand name for the synthetic hormone desmopressin, a structural analogue of the natural antidiuretic hormone vasopressin. It belongs to the hormone therapy class and is supplied as an oral pill containing 200 µg of desmopressin per tablet. In Hong Kong, DDAVP is a prescription-only medication regulated by the Department of Health’s Pharmacy and Poisons Board.

How DDAVP Works in the Body

Desmopressin mimics the action of vasopressin on V2 receptors located in the collecting ducts of the kidneys. Activation of these receptors triggers insertion of aquaporin-2 water channels into the tubular membrane, allowing more water to be re-absorbed back into the bloodstream. The result is a reduction in urine volume (antidiuretic effect) and an increase in urine concentration.

Because desmopressin has minimal activity at V1 receptors, it does not cause the vasoconstrictive effects (e.g., increased blood pressure) that natural vasopressin can produce. The onset of action after oral ingestion is typically within 30-60 minutes, with peak effect around 2 hours and a duration of action of 6-12 hours, depending on individual renal function.

Conditions Treated by DDAVP

DDAVP is approved in Hong Kong for the following indications:

• Central Diabetes Insipidus (CDI) - a disorder in which the brain does not produce enough vasopressin, leading to excessive urination and thirst.
• Nocturnal Enuresis in children and adolescents - bed-wetting that occurs at least twice per week despite standard behavioral measures.
• Hemophilia A and von Willebrand Disease (vWD) - both conditions benefit from desmopressin’s ability to raise circulating levels of clotting factor VIII and von Willebrand factor, thereby improving hemostasis for minor procedures or bleeding episodes.

These uses are supported by regulatory approval and clinical guidelines within the Hong Kong health system.

Off-Label and Investigational Applications

Evidence from peer-reviewed studies suggests that desmopressin may have utility in the following off-label contexts, although they are not approved by the Hong Kong Department of Health:

• Primary Polydipsia - limited case series show modest benefit, but controlled trials are lacking.
• Bleeding prophylaxis for Minor Dental Procedures in vWD carriers - guideline-based recommendations allow off-label use when factor levels are borderline, provided that treatment is supervised by a hematologist.

Disclaimer: Off-label use requires medical supervision, individualized risk assessment, and should follow local clinical guidelines.

Who Should (Not) Use DDAVP?

Ideal Patient Characteristics

• Adults or children with confirmed central diabetes insipidus, nocturnal enuresis, or a documented bleeding disorder (hemophilia A or vWD) who require antidiuretic or hemostatic support.
• Patients with stable renal function (eGFR ≥ 30 mL/min/1.73 m²) unless dose is adjusted under specialist guidance.

Absolute Contraindications

• Known hypersensitivity to desmopressin or any excipients in the tablet.
• Severe hyponatraemia (serum sodium < 125 mmol/L).
• Chronic kidney disease with eGFR < 30 mL/min/1.73 m² unless a nephrologist advises otherwise.
• Uncontrolled congestive heart failure or severe pulmonary edema.

Relative Contraindications

• Moderate renal impairment (eGFR 30-60 mL/min/1.73 m²).
• Pregnancy (especially first trimester) - limited human data; use only if potential benefit outweighs risk.
• Lactation - desmopressin is excreted in small amounts in breast milk; monitor infant for signs of water retention.

Special Populations

• Elderly: May be more sensitive to antidiuretic effects; start at the lowest effective dose and monitor sodium levels.
• Pediatrics: Dosing is weight-based; the 200 µg tablet can be split under pharmacist supervision for appropriate pediatric doses.

Safety Profile and Interactions

Common Side Effects

• Headache - usually mild and transient.
• Nausea or abdominal discomfort - often resolves with continued therapy.
• Facial flushing - occasional, self-limiting.

Serious Adverse Events

• Hyponatraemia - can be severe, presenting with confusion, seizures, or coma; requires immediate medical attention.
• Fluid overload - especially in patients with cardiac or renal dysfunction, leading to edema or pulmonary congestion.
• Allergic reactions - rare but may include rash, itching, or angioedema.

Drug Interactions

• CYP-independent interactions: Drugs that increase free water retention (e.g., thiazide diuretics, carbamazepine, tricyclic antidepressants) may potentiate hyponatraemia.
• Warfarin: Desmopressin can augment the hemostatic effect; monitor INR closely when both are used.
• NSAIDs: May impair renal prostaglandin synthesis, enhancing antidiuretic action and raising the risk of fluid overload.

Practical tip: Always provide a complete medication list-including over-the-counter products and herbal supplements-to the prescribing clinician before starting DDAVP.

Food and Lifestyle Interactions

• Fluid intake: Patients are advised to restrict excessive water consumption, especially during the first 24 hours after initiating therapy.
• Alcohol: Moderate intake is permissible, but excessive drinking can worsen hyponatraemia.
• Driving or operating machinery: Desmopressin does not impair cognition; however, severe hyponatraemia can cause confusion, so patients should seek medical care promptly if symptoms arise.

How to Take DDAVP

• Standard adult dosing: One 200 µg tablet taken orally once daily, preferably in the morning for diabetes insipidus or at bedtime for nocturnal enuresis.
• Dose adjustments: The tablet may be split to achieve a 100 µg dose if a lower regimen is needed. Any increase beyond the initial dose should be made only under physician supervision.
• Renal or hepatic impairment: Reduce the dose (e.g., 100 µg once daily) and monitor serum sodium and fluid balance closely.
• Administration: Swallow the tablet whole with a glass of water; crushing or chewing is not recommended because it may alter absorption.
• Missed dose: Take the missed tablet as soon as remembered, unless it is near the time of the next scheduled dose. Do not double the dose.
• Overdose: Symptoms may include severe hyponatraemia, seizures, or profound lethargy. Seek emergency medical care; treatment focuses on careful correction of sodium levels and fluid restriction.
• Discontinuation: Gradual tapering is generally unnecessary for short-term use, but abrupt cessation in chronic diabetes insipidus may lead to rebound polyuria; therefore, follow-up with a healthcare provider for a personalized plan.

Monitoring and Follow-Up

• Serum sodium: Check baseline, then 3-5 days after initiating therapy, and periodically thereafter (every 1-3 months) for chronic users.
• Fluid balance: Record daily urine output and fluid intake for the first week to assess therapeutic response.
• Bleeding disorders: For hemophilia A or vWD patients, measure factor VIII and von Willebrand factor levels 30 minutes after dosing when used for procedural prophylaxis.
• Renal function: Periodic eGFR assessment is advised for patients with known kidney disease.

Patients should contact their healthcare provider promptly if they develop signs of hyponatraemia (e.g., headache, nausea, confusion, seizures) or unexpected weight gain/edema.

Storage and Handling

• Keep DDAVP tablets in the original container, tightly closed.
• Store at room temperature (20-25 °C), protected from moisture and direct sunlight.
• Do not use tablets that are discolored, cracked, or past the printed expiration date.
• Keep out of reach of children; consider a child-proof cabinet.
• For disposal, follow local guidelines for medication waste-typically a pharmacy take-back program or the Hong Kong Environmental Protection Department’s household waste instructions.

Medication-Specific Glossary

V2 Receptor

A protein on the renal collecting-duct cells that, when activated by desmopressin, triggers water channel insertion and promotes water re-absorption.

Antidiuretic Effect

The physiological outcome of reduced urine volume and increased urine concentration caused by enhanced water re-absorption in the kidneys.

Desmopressin

A synthetic analogue of vasopressin with selective activity on V2 receptors, used to treat disorders of water balance and certain bleeding conditions.

Hyponatraemia

A potentially dangerous low concentration of sodium in the blood, often defined as serum sodium < 135 mmol/L; may result from excess water retention.

Factor VIII

A clotting protein that works with von Willebrand factor to form stable blood clots; its level rises after desmopressin administration in hemophilia A patients.

Medical Disclaimer

This article provides educational information about DDAVP and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.